Document is current

Article History

Received: 22 September 2025

Accepted: 8 May 2026

First Online: 21 May 2026

Declarations

Ethics Approval and Consent to Participate: The study protocol was approved by the Institutional Review Board and/or Independent Ethics Committee and local data protection agencies. Adherence to legal, regulatory, and other applicable guidelines (as mentioned in sub-Sect.  2.4 “Ethics” of this publication) ensured scientific integrity. Due to the retrospective nature of the study, patient informed consent was not required and not collected.

Consent to Publish: Consent to publish was not required or collected because all patient information was anonymised and aggregated, and the submission does not include personally identifiable images.

Competing interests: AT, AK, KP, KKup, LJ, and NM are employees of Pfizer and may hold stock/stock options with Pfizer. AP is a former employee of Pfizer. AMO, JLMG, JLM, KKum, SB, TF, and VE declare no conflicts of interest. Micron Research Ltd. have received funding from Pfizer for data management, statistics and authoring of the CSR on the CODAR study. AG and RK have received honoraria or consultation fees from Micron Research Ltd. in the last three years, which are related to the submitted work. AS has received institutional grants or research support from Pfizer for the submitted study-related activities. AW has received honoraria or consultation fees from Medtronic. RFC has received honoraria or consultation fees from Pfizer, MSD, and Biomerieux, and institutional grants or research support from Pfizer. YP has received honoraria or consultation fees from Pfizer. MA has received honoraria or consultation fees from Pfizer, Merk and Shionogi.